


MEDICINAL PRODUCTS 2023

VOLITIONRX LTD Rank 44 of 48









MEDICINAL PRODUCTS 2023

VOLITIONRX LTD Rank 44 of 48



The relative strengths and weaknesses of VOLITIONRX LTD are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VOLITIONRX LTD compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 22% points. The greatest weakness of VOLITIONRX LTD is the variable Net Income, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is -167%, being 162% points below the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	12,172
Assets, Non-Current	619
General and Administrative Expense	17,514
Goodwill	111
Liabilities, Current	17,386
Liabilities, Non-Current	3,179
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	857
Other Net Income	0
Other Revenues	1,488
Property, Plant and Equipment, Net	5,393
Research and Development	14,573

Output Variable	Value in 1000 USD
Liabilities	21,422
Assets	18,295
Expenses	32,086
Revenues	1,488
Stockholders Equity	-3,127
Net Income	-30,598
Comprehensive Net Income	-30,598
Economic Capital Ratio	-167%

